Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib with nivolumab and/or ipilimumab versus rucaparib alone in homologous repair deficient relapsed ovarian cancer
2017-004780-13Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Rucaparib alone, Rucaparib + nivolumab and Rucaparib + nivolumab + ipilimumab (3 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2017-004780-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004780-13.